AKLI vs. CODX, GBS, RVP, MODD, FEMY, NMTC, XAIR, MDAI, ICU, and CTCX
Should you be buying Akili stock or one of its competitors? The main competitors of Akili include Co-Diagnostics (CODX), GBS (GBS), Retractable Technologies (RVP), Modular Medical (MODD), Femasys (FEMY), NeuroOne Medical Technologies (NMTC), Beyond Air (XAIR), Spectral AI (MDAI), SeaStar Medical (ICU), and Carmell (CTCX). These companies are all part of the "surgical & medical instruments" industry.
Co-Diagnostics (NASDAQ:CODX) and Akili (NASDAQ:AKLI) are both small-cap medical companies, but which is the better business? We will compare the two companies based on the strength of their profitability, institutional ownership, valuation, risk, analyst recommendations, media sentiment, earnings, community ranking and dividends.
Co-Diagnostics presently has a consensus price target of $2.00, suggesting a potential upside of 83.52%. Akili has a consensus price target of $4.00, suggesting a potential upside of 852.61%. Given Co-Diagnostics' stronger consensus rating and higher probable upside, analysts clearly believe Akili is more favorable than Co-Diagnostics.
In the previous week, Co-Diagnostics had 6 more articles in the media than Akili. MarketBeat recorded 10 mentions for Co-Diagnostics and 4 mentions for Akili. Co-Diagnostics' average media sentiment score of 0.10 beat Akili's score of -0.17 indicating that Akili is being referred to more favorably in the news media.
15.0% of Co-Diagnostics shares are held by institutional investors. Comparatively, 53.1% of Akili shares are held by institutional investors. 2.4% of Co-Diagnostics shares are held by company insiders. Comparatively, 10.1% of Akili shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.
Co-Diagnostics has higher revenue and earnings than Akili. Co-Diagnostics is trading at a lower price-to-earnings ratio than Akili, indicating that it is currently the more affordable of the two stocks.
Co-Diagnostics has a net margin of -582.36% compared to Co-Diagnostics' net margin of -2,492.04%. Akili's return on equity of -42.35% beat Co-Diagnostics' return on equity.
Co-Diagnostics has a beta of -0.65, suggesting that its stock price is 165% less volatile than the S&P 500. Comparatively, Akili has a beta of 1.7, suggesting that its stock price is 70% more volatile than the S&P 500.
Co-Diagnostics received 267 more outperform votes than Akili when rated by MarketBeat users. However, 66.67% of users gave Akili an outperform vote while only 63.34% of users gave Co-Diagnostics an outperform vote.
Summary
Akili beats Co-Diagnostics on 11 of the 18 factors compared between the two stocks.
Get Akili News Delivered to You Automatically
Sign up to receive the latest news and ratings for AKLI and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding AKLI and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Related Companies and Tools
